Risk of stroke, atrial fibrillation, and major bleeding after mitral valve repair: the jury is still out

EuroIntervention 2020;15:1387-1389. DOI: 10.4244/EIJV15I16A251

Daniele Giacoppo
Daniele Giacoppo1,2,3, MD, MSc; Giuseppe Tarantini1, MD, PhD
1. Cardiac-Thoracic-Vascular Department, University of Padua, Padua, Italy; 2. Alto Vicentino Hospital, Santorso, Vicenza, Italy; 3. Deutsches Herzzentrum München, Munich, Germany

In recent years, edge-to-edge transcatheter mitral valve repair (TMVR) has emerged as an acceptable therapeutic option for inoperable or high surgical risk patients suffering from severe mitral valve regurgitation1,2,3. The main advantages of TMVR over traditional surgical approaches – hereinafter referred to as surgical mitral valve repair (SMVR) – are its limited invasiveness and favourable safety profile, though clinical outcomes and functional cardiac parameters remain significantly inferior at long-term follow-up1,2.

In large registries, the incidence of clinically overt stroke after TMVR is reported to be very low, ranging from 0.2% to 0.4% at discharge and from 0.7% to 0.8% at 30 days4,5,6,7. However, ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Myocardial fibrosis in severe aortic stenosis: how and when should we measure it?

Latest news